Katharina Wang, Laura Schober, Alessa Fischer, Nicole Bechmann, Julian Maurer, Lea Peischer, Astrid Reul, Constanze Hantel, Martin Reincke, Felix Beuschlein, Mercedes Robledo, Hermine Mohr, Natalia S Pellegata, Katharina Schilbach, Thomas Knösel, Matthias Ilmer, Martin Angele, Matthias Kroiss, Umberto Maccio, Martina Broglie-Däppen, Diana Vetter, Kuno Lehmann, Karel Pacak, Ashley B Grossman, Christoph J Auernhammer, Kathrin Zitzmann, Svenja Nölting
CONTEXT: Treatment options for advanced neuroendocrine tumors (NETs), pheochromocytomas and paragangliomas (together PPGLs) are still limited. In recent years, anti-tumor effects of cannabinoids have been reported; however, there are only very limited data available in NETs or PPGLs. OBJECTIVE: Investigation of the effects of cannabidiol (CBD) on patient-derived human NET/PPGL primary cultures and on NET/PPGL cell lines. METHODS: We established primary cultures derived from 46 different patients with PPGLs (n = 35) or NETs (n = 11) who underwent tumor resection at two centers...
April 12, 2024: Journal of Clinical Endocrinology and Metabolism